
Cannabis-focused pharmaceutical company MediCane Health Inc. announced the awarding of an IMC-GMP license for its new manufacturing facility in Kfar Saba, Israel. The approval received this month will enable MediCane to manufacture dry herb and cannabis-based oils, as well as to produce novel formulations for its in-house R&D activity.
Together with its wide network of research partners, MediCane is conducting clinical programs to develop cannabis-based drugs with two leading therapeutic areas - behavioral and psychological symptoms of dementia (BPSD) and sleep disorders.